A Study to Evaluate the Impact of Pre-procedural Intracoronary Nicorandil Injection to PREVENT ReductioN of DecREased TIMI FLOW in Patients Who Undergoing Percutaneous Coronary Intervention for the Coronary Artery Disease
Recruiting now · Phase 4
Conditions studied: No-Reflow Phenomenon, Coronary Artery Disease, Percutaneous Coronary Intervention
In brief
The aim of this study was to determine the effect of intra-coronary administration of nicorandil on the prevention of lowering of coronary blood flow for high-risk plaque lesions defined as the high value of lipid core burden index in patients with coronary artery disease who require stent treatment.
Key facts
- Study ID
- NCT05427786
- Run by
- Korea University Anam Hospital
- People needed
- 460
- Starts
- 2022-12-14
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2024-10-10
Who can join
Age: 19 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Over 19 years old
- Patients who agree to the study plan and clinical follow-up plan, voluntarily decide to participate in this study, and consent in writing to the consent to use information
- Patients who underwent NIRS-IVUS guided coronary stent surgery for coronary artery disease
You may not qualify if…
- Patients with TIMI ≤ 2 before coronary intervention
- Subjects with known hypersensitivity or contraindications to the following drugs or substances: heparin, aspirin, clopidogrel, ticagrelor, prasugrel, rosuvastatin, ezetimibe, evolocumab, lansoprazole, cobalt chromium, stainless steel nickel And contrast agents (however, even a subject who is hypersensitive to contrast agents can register if they can be controlled by steroids and pheniramine, except for known anaphylaxis.)
- Pregnant women, lactating women, or women of childbearing age who plan to become pregnant during this study
- Subjects who plan to have surgery to stop antiplatelet drugs within 6 months from registration
- Those whose surviving life is expected to be less than 1 year
- Subjects who visited the hospital due to cardiogenic shock and are predicted to have low survival probability based on medical judgment
Where it is running
- Korea University Anam Hospital — Seoul, South Korea (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.